A 52 WEEK, 2 ARM RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL ASSESSING THE EFFICACY AND SAFETY OF IANALUMAB IN PATIENTS WITH SJOGREN'S DISEASE WITH A GLANDULAR PREDOMINANT PHENOTYPE-HIGH SYMPTOM BURDEN AND LOW SYSTEMIC DISEASE ACTIVITY (THALASSA)
- Registry ID
- CVAY736A22301
- Source registry
- HEALTH_CANADA
- Status
- Pending
- Study type
- INTERVENTIONAL
- Sponsor
- NOVARTIS PHARMACEUTICALS CANADA INC
- Last update
- 2026-05-21
Conditions
Related clinical trials
- A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, MULTICENTER PHASE
3 PROTOCOL TO ASSESS THE EFFICACY AND SAFETY OF NIPOCALIMAB IN ADULTS
WITH MODERATE TO SEVERE SJÖGREN'S DISEASE (SJD)
- A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAZODALIBEP IN PARTICIPANTS WITH SJOGREN'S SYNDROME WITH MODERATE TO SEVERE SYMPTON STATE
- A RANDOMIZED, DOUBLE-BLIND 2-ARM NEPTUNUS EXTENSION STUDY TO ACCESS THE LONG-TERM SAFETY AND EFFICACY OF IANALUMAB IN PATIENTS WITH SJOGREN'S SYNDROME
- A 48-WEEK, 6-ARM, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER TRIAL TO ASSESS THE SAFETY AND EFFICACY OF MULTIPLE CFZ533 DOSES ADMINISTERED SUBCUTANEOUSLY IN TWO DISTINCT POPLUATIONS OF PATIENTS WITH SJOGREN'S SYNDROME (TWINSS)
View on source registry